NASDAQ:NBIX • US64125C1099
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROCRINE BIOSCIENCES INC (NBIX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-24 | Wolfe Research | Initiate | Outperform |
| 2026-02-17 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-12 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2026-02-12 | Needham | Maintains | Buy -> Buy |
| 2026-02-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-12 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-12 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-23 | UBS | Maintains | Buy -> Buy |
| 2026-01-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-08 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-08 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-12-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-12 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-12-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-11 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-30 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-29 | Needham | Maintains | Buy -> Buy |
| 2025-10-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.887B 26.76% | 2.355B 24.81% | 2.861B 21.45% | 3.514B 22.85% | 3.865B 9.99% | 4.259B 10.19% | 4.37B 2.61% | 4.7B 7.55% | 5.346B 13.74% | 5.644B 5.57% | 5.969B 5.76% | |
| EBITDA YoY % growth | 416.1M 56.25% | 610.1M 46.62% | 666.6M 9.26% | 738.07M 10.72% | 942.73M 27.73% | 1.236B 31.11% | 1.377B 11.41% | 1.58B 14.74% | 2.364B 49.62% | 3.137B 32.70% | 3.637B 15.94% | |
| EBIT YoY % growth | 394.8M 57.48% | 583M 47.67% | 636.5M 9.18% | 812.45M 27.64% | 1.055B 29.85% | 1.346B 27.58% | 1.406B 4.46% | 1.7B 20.91% | 2.599B 52.88% | 2.858B 9.97% | 3.357B 17.46% | |
| Operating Margin | 20.92% | 24.75% | 22.25% | 23.12% | 27.30% | 31.60% | 32.17% | 36.17% | 48.62% | 50.64% | 56.24% | |
| EPS YoY % growth | 2.42 58.17% | 3.29 35.95% | 4.66 41.64% | 6.11 31.12% | 8.29 35.71% | 10.55 27.22% | 13.38 26.83% | 15.29 14.28% | 16.18 5.84% | 17.50 8.11% | 19.63 12.21% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.22 1,431.05% | 1.46 37.67% | 1.89 -7.27% | 2.04 38.09% |
| Revenue Q2Q % growth | 790.45M 38.05% | 866.63M 26.06% | 891.09M 12.10% | 927.66M 15.17% |
| EBITDA Q2Q % growth | 164.99M 427.12% | 188.68M 17.56% | 217.2M -17.07% | 139.63M -45.88% |
| EBIT Q2Q % growth | 146.52M 518.23% | 195.46M 34.24% | 248.22M 3.73% | 291.11M 27.74% |
All data in USD
36 analysts have analysed NBIX and the average price target is 179.61 USD. This implies a price increase of 40.88% is expected in the next year compared to the current price of 127.49.
NEUROCRINE BIOSCIENCES INC (NBIX) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of NEUROCRINE BIOSCIENCES INC (NBIX) is 1.22 USD and the consensus revenue estimate is 790.45M USD.
The number of analysts covering NEUROCRINE BIOSCIENCES INC (NBIX) is 36.